ATE320502T1 - Für eine glutamat-dekarboxylase-aktivität kodierende rekombinierende viren - Google Patents

Für eine glutamat-dekarboxylase-aktivität kodierende rekombinierende viren

Info

Publication number
ATE320502T1
ATE320502T1 AT95914389T AT95914389T ATE320502T1 AT E320502 T1 ATE320502 T1 AT E320502T1 AT 95914389 T AT95914389 T AT 95914389T AT 95914389 T AT95914389 T AT 95914389T AT E320502 T1 ATE320502 T1 AT E320502T1
Authority
AT
Austria
Prior art keywords
virus
glutamate decarboxylase
recombining
contg
decarboxylase activity
Prior art date
Application number
AT95914389T
Other languages
English (en)
Inventor
Alexis Bemelmans
Marie-Claude Geoffroy
Philippe Horellou
Jean-Francois Julien
Jacques Mallet
Michel Perricaudet
Jean-Jacques Robert
Emmanuelle Vigne
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9403411A external-priority patent/FR2717823B1/fr
Priority claimed from FR9413487A external-priority patent/FR2726575B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE320502T1 publication Critical patent/ATE320502T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT95914389T 1994-03-23 1995-03-21 Für eine glutamat-dekarboxylase-aktivität kodierende rekombinierende viren ATE320502T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9403411A FR2717823B1 (fr) 1994-03-23 1994-03-23 Virus recombinants, préparation et utilisation en thérapie génique.
FR9413487A FR2726575B1 (fr) 1994-11-09 1994-11-09 Virus recombinants, preparation et utilisation en therapie genique

Publications (1)

Publication Number Publication Date
ATE320502T1 true ATE320502T1 (de) 2006-04-15

Family

ID=26231035

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914389T ATE320502T1 (de) 1994-03-23 1995-03-21 Für eine glutamat-dekarboxylase-aktivität kodierende rekombinierende viren

Country Status (13)

Country Link
US (1) US20020028212A1 (de)
EP (2) EP0752003B1 (de)
JP (1) JPH09511394A (de)
KR (1) KR100403893B1 (de)
AT (1) ATE320502T1 (de)
AU (1) AU2140695A (de)
CA (1) CA2184297C (de)
DE (1) DE69534873T2 (de)
FI (1) FI963755A (de)
IL (1) IL113052A0 (de)
MX (1) MX9604026A (de)
NO (1) NO963806D0 (de)
WO (1) WO1995025805A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001213773A (ja) * 2000-01-31 2001-08-07 Yaegaki Hakko Giken Kk 高血圧および糖尿病改善剤とγ−アミノ酪酸の製造方法
AU6808001A (en) 2000-05-23 2001-12-03 Neurologix Inc Glutamic acid decarboxylase (gad) based delivery systems
US7695959B2 (en) * 2000-05-23 2010-04-13 Neurologix, Inc. Glutamic acid decarboxylase (GAD) based delivery systems
US20160136095A1 (en) * 2014-11-18 2016-05-19 PixarBio Corporation Methods for treating epilepsy or seizure disorders
WO2017123676A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
EP0228458B2 (de) 1985-07-05 1997-10-22 Whitehead Institute For Biomedical Research Expression von fremdem genetischem material in epithelzellen
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
EP0289034B1 (de) 1987-05-01 1996-11-27 The General Hospital Corporation Transkaryotische Einpflanzung
AU3069189A (en) 1988-02-05 1989-08-25 Trustees Of Columbia University In The City Of New York, The Retroviral packaging cell lines and processes of using same
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5270452A (en) * 1988-11-28 1993-12-14 Rhone-Poulenc Rorer Pharmaceuticals Inc. Pure glia maturation factor
JPH04507041A (ja) 1988-12-13 1992-12-10 アメリカ合衆国 遺伝工学により修飾された内皮細胞およびその利用方法
JP2814529B2 (ja) * 1989-03-16 1998-10-22 味の素株式会社 虚血性脳障害治療薬
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
ES2217250T3 (es) * 1990-06-15 2004-11-01 Scios Inc. Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
US6682906B1 (en) * 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5189026A (en) * 1991-06-07 1993-02-23 Fractal Laboratories, Inc. Treatment of human diseases involving dysregulation or dysfunction of the nervous system
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0641330B1 (de) * 1992-05-20 2001-10-17 Northwestern University Gaba und l-glutaminsaüre analoga zur behandlung der epilepsie
JPH08501686A (ja) * 1992-09-25 1996-02-27 ローン−プーラン・ロレ・ソシエテ・アノニム 中枢神経系、特に脳における細胞への外来遺伝子の転移のためのアデノウィルスベクター
FR2702152B1 (fr) * 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2707664B1 (fr) 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins

Also Published As

Publication number Publication date
CA2184297C (fr) 2009-09-29
US20020028212A1 (en) 2002-03-07
IL113052A0 (en) 1995-06-29
FI963755A0 (fi) 1996-09-20
FI963755A (fi) 1996-09-20
DE69534873T2 (de) 2006-11-16
NO963806L (no) 1996-09-11
DE69534873D1 (de) 2006-05-11
NO963806D0 (no) 1996-09-11
KR100403893B1 (ko) 2004-02-19
KR970701785A (ko) 1997-04-12
JPH09511394A (ja) 1997-11-18
CA2184297A1 (fr) 1995-09-28
MX9604026A (es) 1997-09-30
EP1681354A2 (de) 2006-07-19
EP0752003A1 (de) 1997-01-08
AU2140695A (en) 1995-10-09
EP0752003B1 (de) 2006-03-15
EP1681354A3 (de) 2010-08-11
WO1995025805A1 (fr) 1995-09-28

Similar Documents

Publication Publication Date Title
DK1394179T3 (da) Fremgangsmåde til fremstilling af erythropoietin fri for animalske proteiner
ATE125869T1 (de) Wachstumshormonfusionsproteine.
EP1005376A4 (de) Methoden und zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
DK374689D0 (da) Dna-sekvenser, som koder for polypeptider med beta-1,3-glucanaseaktivitet
UA39161C2 (uk) Рекомбінантний білок gm-csf для збільшення продукції гранулоцитів і макрофагів у пацієнтів, вектор і кднк, що його кодують
ATE284954T1 (de) Hyaluronan synthase gen und seine verwendung
ATE92105T1 (de) Expression von faktor-vii-aktivitaet in saeugetierzellen.
JPS6485084A (en) Constellation of protein c
ATE318912T1 (de) Polynukleotid kodierend für ein polypeptid mit heparanase-aktivität und dessen expression in transduzierten zellen
NO981044D0 (no) Sirkulært DNA-molekyl med kondisjonell replikasjonsopprinnelse, dets fremstilling og anvendelse derav i genterapi
ATE93272T1 (de) Expression von protein c.
AU682140B2 (en) Multidrug resistance gene
AU637139B2 (en) Gm-csf protein, its derivatives, the preparation of proteins of this type, and their use
DE69516416D1 (de) Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen
ATE320502T1 (de) Für eine glutamat-dekarboxylase-aktivität kodierende rekombinierende viren
DE60039677D1 (de) Akt-3 nukleinsäure, polypeptide und deren verwendung
ATE127840T1 (de) Charakterisierung und struktur der gene für protease a und protease b von streptomyces griseus.
NO891587D0 (no) Fremgangsmaate for fremstilling av proteinholdige materiale ved dyrking av celler som inneholder rekombinante avipoxvirusvektorer.
EA200401390A1 (ru) N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения
ES8605296A1 (es) Procedimiento de producir factor viii-r humano
IL108584A0 (en) Cloning of interferon - alpha beta binding protein
NO179453C (no) Fremgangsmåte for fremstilling av terapeutisk aktivt amphiregulin, vertscelle som produserer proteinet, rekombinant vektor inneholdt i vertscellen, samt nukleotidsekvens som koder for proteiner med amphiregulinaktivitet
NO941982L (no) Fremstilling av proteiner ved anvendelse av 7B2 protein
NO944878L (no) Modifisert Kluyveromyces-gjær, dens fremstilling og anvendelse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties